Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
oh, by the way... Outstanding Shares 15,822,137 12/31/2020
It is a solid play, the market cap is way under the value of the day today, let alone tomorrow.
I am looking at a long term hold here, I think it merits that.
Amazing news!!! That makes this a very solid play
Medigus Ltd. Announces Record High Financial Results
Revenues for the first half of 2021 increased by ~3,178% with first ever net profit of approximately $8 million
OMER, Israel, September 20, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions,
innovative internet technologies and electric vehicle and charging solutions, announced today its financial results for the first six months ended June 30, 2021.
? Revenues for the six-month period ended June 30, 2021, reached a record high, and totaled $2,393,000, an increase of $2,320,000 compared to $73,000 in
the six-month period ended June 30, 2020
? Net income for the period reached a record of $7,927,000 compared to a net loss of $3,599,000 in the six-month period ended June 30, 2020
? Shareholders’ equity totaled $53,904,000 as of June 30, 2021
? Cash and cash equivalents totaled $29,642,000 as of June 30, 2021
$MDGS is awesome but also take a look at $MDGSW the low float warrants. I think if $MDGS runs, the warrants will REALLY run because of the small float. I think this is an even bigger opportunity than the stock itself.
If you can’t buy NASDAQ stocks after hours, this is your last chance to grab some $MDGS before regular market hours close. Look at the chart, strong second half of the day here. That will continue after hours swing play overnight on this one. They dropped some big news today about their revenues (astonishing numbers). There’s a reason why analysts are saying this will go to $6 a share.
Red day all over the markets .. but not here!!
Holding green today with the news out
And the price is currently on a swing up
This will be a good run, look at the revenue numbers then look at the market cap
Market Cap 1,170,838 09/17/2021
Huge news there on patents and now the revenue news today. This stock will indeed reach the $4 plus targets by analysts
These revenues are very solid. It’s very impressive news today. Once the market responds … watch for a big run
Here’s a dip opportunity, with this big news dropped today, we won’t see these prices for long
$MDGS
$MDGSW
Is a play that just dropped some huge news!
Their revenues are absolutely amazing here. Revenues for the six-month period ended June 30, 2021, reached a record high, and totaled $2,393,000, an increase of $2,320,000 compared to $73,000 in the six-month period ended June 30, 2020. Net income for the period reached a record of $7,927,000 compared to a net loss of $3,599,000 in the six-month period ended June 30, 2021. Cash and cash equivalents totaled $29,642,000 as of June 30, 2021. Tell me those aren’t amazing numbers that will make these stocks soar!
Medigus: Polyrizon to Test its Product Candidate for Protection Against High Transmissible Corona Virus Delta Variant B.1.617.2
Medigus Ltd
Thu, September 9, 2021, 4:45 AM
In this article:
In recent pre- clinical studies, Polyrizon products showed strong potential in preventing human coronavirus 229E and Influenza Virus H1N1 from interacting with epithelial host cells and by inhibiting cells' death.
OMER, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, will evaluate the viral infection prophylaxis effect of its innovative product candidate against the Delta variant of the coronavirus(lineage B.1.617.2), in-vitro. This study follows recent pre-clinical studies showed strong potential against human coronavirus 229E and influenza virus infection.
The Delta variant has mutations in the gene encoding the SARS-CoV-2 spike protein causing the substitutions T478K, P681R and L452R, which are known to affect transmissibility of the virus. As a result, the Delta variant has been found to be more contagious than the other coronavirus strains.
In the upcoming study, Polyrizon will assess the protection effect of its Capture and Contain (C&C™) platform against the highly transmissible Delta variant. The study is planned to begin in Q4 2021.
The predominant COVID-19 Delta strain has put the focus back on transmission prevention where layered prevention solutions are needed to reduce the transmission of the Delta variant. Polyrizon’s C&C™ platform focuses on preventative approaches that when combined with vaccination, social distancing and mask usage should further decrease the risk of infection.
Last week, Polyrizon submitted an additional patent application to the United States Patent and Trademark Office for its innovative technology.
The invention generally pertains to the field of hydrogels that are capable of capturing and containing biological assaults intrusion through the upper airways and eye cavities. Furthermore, the invention details a novel modality for a delivery system for drugs through the nasal mucosa that may be able to deliver a higher drug dosage into the body and reside longer in the nasal cavity.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technologies company that is focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce, and electric vehicle markets. Medigus' affiliations in the medical solutions arena consist of ownership in ScoutCam (OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff's Brands and Eventer Technologies, Ltd. In the electric vehicle market, Charging Robotics, Ltd. and Revolz are also part of the Company’s portfolio of technology solution providers. Medigus is traded on the Nasdaq Capital Market. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/investor-relations.
Cautionary Note Regarding Forward Looking Statements
This press release may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of Medigus’ management and its knowledge of the relevant market. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. For example, Medigus uses forward looking statements when describing Polyrizon’s upcoming study. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Medigus’ activity to differ significantly from the content and implications of such statements. Other risk factors affecting Medigus and Polyrizon are discussed in detail in the Medigus’ filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and Medigus undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither Medigus nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Medigus’ securities. Nothing in this press release should be deemed to be medical or other advice of any kind.
Contact
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Medigus: Polyrizon Submits a Patent Application for Prevention of Pathogens such as Coronavirus and Allergens from Affecting Nasal Tissue Press Release | 09/02/2021
In recent pre- clinical studies, Polyrizon products showed strong potential by preventing coronavirus and Influenza Virus H1N1 from interacting with epithelial host cells and by inhibiting cells' death.
OMER, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, has submitted an additional patent application to the United States Patent and Trademark Office for its innovative technology.
The invention generally pertains to the field of hydrogels that are capable to capture and contain biological assaults intrusion through the upper airways and eye cavities. Furthermore, the invention details a novel modality for a delivery system for drugs through the nasal mucosa that could get more drug into the body, and resides longer in the nasal cavity.
Recent pre-clinical data by Polyrizon, showed that its product candidate has the potential to reduce the risk of an infection with human coronavirus and may also prevent COVID-19 as well as Influenza Virus H1N1 and may potentially also treat additional Cold viruses.
Polyrizon’s product candidate protects the nasal cavity and the respiratory tract, prevents the virus from colonizing in the upper respiratory, potentially decreases the viral load and facilitates the immune system to control the virus more effectively.
This pre-clinical data highlights the Capture and Contain (C&C™) impact of Polyrizon’s product line that can be extended against Coronavirus, Influenza and Cold viruses and a variety of different respiratory viruses.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technologies company that is focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce, and electric vehicle markets. Medigus' affiliations in the medical solutions arena consist of ownership in ScoutCam (OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff's Brands and Eventer Technologies, Ltd. In the electric vehicle market, Charging Robotics, Ltd. and Revolz are also part of the Company’s portfolio of technology solution providers. Medigus is traded on the Nasdaq Capital Market. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/investor-relations.
Cautionary Note Regarding Forward Looking Statements
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technologies company that is focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce, and electric vehicle markets. Medigus' affiliations in the medical solutions arena consist of ownership in ScoutCam (OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff's Brands and Eventer Technologies, Ltd. In the electric vehicle market, Charging Robotics, Ltd. and Revolz are also part of the Company’s portfolio of technology solution providers. Medigus is traded on the Nasdaq Capital Market. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/investor-relations.
Share Structure
Market Cap 1,162,927
09/03/2021
Authorized Shares
Not Available
Outstanding Shares
15,822,137
12/31/2020
$MDGSW is where I think the big money will be made here. The warrants have a low float and move much better than the main stock
https://money.cnn.com/quote/forecast/forecast.html?symb=MDGS
$120.00 TARGET PRICE ON ALL ANALYSTS BOARDS
https://www.wsj.com/market-data/quotes/MDGS/research-ratings
WOW!!!!
LOOK AT THE TARGET PRICE
Great news today regarding corona virus gel! Traded 6x the OS today! Something is up! For the first full hour of trading this had very good strength! Many caught shorting this need to cover in a few days!
News: Medigus: Eventer Technologies Secures $2.25 Million in pre-IPO Funding Round
Medigus chosen to get delisted from TASE to avoid the constant arbitrage. My 2 cents ....
Can someone please tell me why MDGS got delisted from Isreal.
MDGS:........Electric Vehicle news out just now
Link:
https://finance.yahoo.com/news/medigus-forms-joint-venture-development-131500508.html
(nasdaq-MDGS) MEDIGUS, WORTH LOOKING
Theres 3 big funds- Empery, Hudson bay capital and Sabby management, those 3 funds are holding $2.8 millon warrants at $3.5 million exercise price' this give them the oppurtunity to short the stock every day and to manipulate it for long, long time, Years!LFG BULISH AF
Added that dip, already green again!
MDGS Will drive to and over $5.00 with under 20,000,000 outstanding share and over 51 million market cap..... no float...... Go Mad Dogs..
Medigus is partnering with EMUZE which is is developing and manufacturing high end e-mobility platforms,
electric scooters and alternative personal vehicles.
The company was established by Amir Zaid, a high-profile automotive designer with design work experience at iconic automotive companies such as Fiat, Pininfarina and Ferrari.
Over the last years, an experienced team of brilliant engineers and innovators have worked together to achieve the current cutting edge level of design, performance and durability of our line of products.
Recently, we have joined forces with a well established factory, in order to set up mass production capabilities and to ensure industrial quality standards
https://www.emuzev.com/
Here is the emuze link. I am currently doing research on this company.
What is a micro-mobility vehicle and in what locations/cities are they currently used or would potentially be used?
* * $MDGS Video Chart 11-23-2020 * *
Link to Video - click here to watch the technical chart video
JUST IN: $MDGS Correction: Medigus Signs MOU to Enter Electric Vehicles and Electric Charging Market
Medigus plans to form a joint venture with EMuze founders to develop and potentially commercialize EV-based micro-mobility vehicles for urban and logistics transportation. OMER, Israel, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a techno...
Read the whole news MDGS - Correction: Medigus Signs MOU to Enter Electric Vehicles and Electric Charging Market
* * $MDGS Video Chart 11-19-2020 * *
Link to Video - click here to watch the technical chart video
Just In: $MDGS Medigus Signs MOU to Enter Electric Vehicles and Electric Charging Market
Medigus plans to form a joint venture with EMuze founders to develop and potentially commercialize EV-based micro-mobility vehicles for urban and logistics transportation. General Motors control systems lead Mr. Alon Davidi will act as Medigus’ EV advisor. OMER, Isra...
Read the whole news MDGS - Medigus Signs MOU to Enter Electric Vehicles and Electric Charging Market
Just In: $MDGS Medigus: ScoutCam Approved as Certified Vendor of Israeli Ministry of Defense
OMER, Israel, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq:MDGS) (TASE:MDGS) , a technology company engaged in advanced medical solutions and innovative internet technologies, today announced it was informed that ScoutCam Inc. (OTCQB: SCTC) Medigus’ subsidiary (50.1%) a...
Read the whole news MDGS - Medigus: ScoutCam Approved as Certified Vendor of Israeli Ministry of Defense
Nobody on iHub cares, but PPS goin' up
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
396
|
Created
|
07/28/16
|
Type
|
Free
|
Moderators |
No. 7A, Omer Industrial Park
PO Box 3030
Omer 8496500
Israel
972 72 260 2200
http://www.medigus.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |